secwatch.observer — SEC 8-K summary
======================================

Issuer:     LifeMD, Inc. (LFMD)
CIK:        0000948320
Form:       8-K
Filed at:   2026-08-05T20:10:53+00:00
Accession:  0001493152-26-036170
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LifeMD Q2 revenue $47.3M, adjusted EBITDA loss $3.5M; revises FY2026 guidance
-----------------------------------------------------------------------------

- Revenue $47.3M within guidance; adjusted EBITDA loss $3.5M improved 21% sequentially but below guided range.
- Gross margin expanded ~280 bps YoY to ~89%; total active subscribers up 20% YoY to ~356k.
- Weight management subscribers ~108k; ~95% of new weight patients start on branded GLP-1 therapies.
- Launched telehealth co-marketing with Halozyme's Antares for XYOSTED; expects $2-3M net launch costs in 2026.
- Revises FY2026 guidance: revenue $205.5M-$212.5M, adjusted EBITDA -$6M to breakeven; expects positive adjusted EBITDA in H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/948320/000149315226036170/0001493152-26-036170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/948320/000149315226036170/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-036170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer